Regenxbio Inc（RGNX）股票分析RGNXRegenxbio Inc

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Regenxbio Inc is currently a hold. The stock price is at $9.66, with a recent RSI of 45.861 indicating it is nearing oversold territory. However, the company is facing significant challenges, including an FDA clinical hold on its RGX-121 program, which has led to a 27% drop in stock price recently. Despite insider buying activity suggesting confidence in the company's future, the risks associated with regulatory delays and negative sentiment from analysts, who have lowered price targets significantly, make it prudent to hold rather than buy at this time.

5 analysts cover RGNX: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 29.71.